Sana Biotechnology, Inc. (SANA)
| Market Cap | 1.14B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -297.91M |
| Shares Out | 190.23M |
| EPS (ttm) | -1.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,686,814 |
| Open | 5.55 |
| Previous Close | 6.25 |
| Day's Range | 5.51 - 6.18 |
| 52-Week Range | 3.93 - 23.50 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 13.60 (+126.7%) |
| Earnings Date | Nov 7, 2022 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the tr... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SANA stock is "Buy." The 12-month stock price forecast is 13.6, which is an increase of 126.67% from the latest price.
News
7 Unknown Biotech Stocks That Could Rocket in 2023
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
Sana Biotechnology to Present at September 2022 Investor Conferences
SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its ...
7 Stocks Due for a Stunning Short Squeeze
Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-sque...
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derive...
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppre...
Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including i...
New data highlighting the potential of human islet cell transplantation for type 1 diabetes will be presented New data highlighting the potential of human islet cell transplantation for type 1 diabetes ...
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its p...
Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel f...
SAN FRANCISCO and SUZHOU, China , June 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Sana Biotechnology to build manufacturing in Seattle area, switching from California
After announcing plans last summer to build its manufacturing facility in California, Sana Biotechnology has changed course.
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additiona...
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice Presid...
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its pr...
Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy...
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts coverin...
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
Plans to present data at multiple scientific conferences in 2022
Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its ...
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 Americ...
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data fro...
Biotech IPOs Have Slowed to a Snail's Pace
Sana Biotechnology Inc. ( SANA , Financial) and Lyel Immunopharma Inc. ( LYEL , Financial) are poster children for what's happening in the biotech initial public offering market. The two companies raise...
3 Biotechs That Will Soar Regardless of COVID-19
In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.
Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies
Sana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics. The construc...
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
License will enable Sana's in vivo and ex vivo engineered T cell programs for B cell malignancies
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinica...
Agreement combines IASO Bio and Innovent's CAR construct, validated in clinical trials, with Sana's in vivo and ex vivo engineered cell therapy programs Agreement combines IASO Bio and Innovent's CAR co...
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its p...
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presente...
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy prog...
Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics
Sana Biotechnology has a new $50 million tool in its toolbox.